These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35796627)

  • 1. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
    Yamamoto J; Ito T; Yamaguchi Y; Handa H
    Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component.
    Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA
    Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
    Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
    Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein degraders - from thalidomide to new PROTACs.
    Ito T
    J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
    Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
    Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cereblon in hematologic malignancies.
    Fuchs O
    Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders.
    Kroupova A; Spiteri VA; Rutter ZJ; Furihata H; Darren D; Ramachandran S; Chakraborti S; Haubrich K; Pethe J; Gonzales D; Wijaya AJ; Rodriguez-Rios M; Sturbaut M; Lynch DM; Farnaby W; Nakasone MA; Zollman D; Ciulli A
    Nat Commun; 2024 Oct; 15(1):8885. PubMed ID: 39406745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
    Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD
    Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cereblon as a primary target of IMiDs].
    Ito T; Handa H
    Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents.
    Nutt MJ; Stewart SG
    Drug Discov Today; 2024 Jun; 29(6):104010. PubMed ID: 38704021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
    Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
    Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.